Eleclazine + Placebo to match eleclazine

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ventricular Arrhythmia

Conditions

Ventricular Arrhythmia

Trial Timeline

Sep 1, 2014 → Oct 1, 2016

About Eleclazine + Placebo to match eleclazine

Eleclazine + Placebo to match eleclazine is a phase 2 stage product being developed by Gilead Sciences for Ventricular Arrhythmia. The current trial status is completed. This product is registered under clinical trial identifier NCT02104583. Target conditions include Ventricular Arrhythmia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02104583Phase 2Completed

Competing Products

20 competing products in Ventricular Arrhythmia

See all competitors
ProductCompanyStageHype Score
ONO-1101Ono PharmaceuticalPhase 2
52
ONO-1101Ono PharmaceuticalPhase 2/3
65
Valsartan + Amlodipine + Hydrochlorothiazide + LosartanNovartisPhase 3
77
ranolazineGilead SciencesPhase 2
51
Beta-blocker treatment groupNovo NordiskApproved
84
DIC075VPfizerPhase 1
32
Finerenone (BAY94-8862): intervention A + Finerenone (BAY94-8862): intervention BBayerPhase 1
30
Finerenone (Kerendia, BAY94-8862)BayerPhase 3
74
Finerenone (Kerendia, BAY94-8862) + PlaceboBayerPhase 3
74
Inhaled Iloprost + PlaceboBayerPhase 2
49
Etripamil + Placebo + Etripamil Test DoseMedpacePhase 3
74
Etripamil NS 70 mgMedpacePhase 3
74
Etripamil + PlaceboMedpacePhase 2
49
LevosimendanOrion CorporationPre-clinical
20
Definity® Vial for (Perflutren Lipid Microsphere) Injectable SuspensionLantheus HoldingsApproved
82
Flecainide (monotherapy)Brain BiotechPre-clinical
15
MK0954, /Duration of Treatment : 5 Years + Comparator : atenolol /Duration of Treatment : 5 YearsOrganonPhase 3
72
SGT-501Solid BiosciencesPhase 1
25
Etripamil NS 70 mg + PlaceboMilestone PharmaceuticalsPhase 3
69
Etripamil NSMilestone PharmaceuticalsPhase 3
69